Neutralized monoclonal antibodies individually targeting on TGFβ or dual recognition of TGFβ and PD-1/PDL-1 have achieved significant antitumor effects in treatment of liver cancer, pancreatic cancer, lung cancer, and urethral cancer (108, 109). This evidence concerns the gene TGFB1 and lung carcinoma.